Hyderabad

Natco Pharma donates chloroquine phosphate tablets for trial

Natco Pharma has donated chloroquine phosphate tablets through its marketing partner in the U.S., Rising Pharmaceuticals, to support a global clinical trial conducted by the CROWN Collaborative, for protecting essential healthcare workers from COVID-19.

Stating this, a release from the Hyderabad-headquartered drug maker said Washington University School of Medicine in St. Louis is the clinical coordinating centre for this ambitious international trial. The group, called the COVID-19 Research Outcomes Worldwide Network (CROWN) Collaborative, is testing whether the anti-malaria drug chloroquine can prevent COVID-19 infection or decrease its severity in frontline healthcare workers. For this study, chloroquine will be donated to the U.S. arm of the Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION (CROWN CORONATION) clinical trial.

The Collaborative and the trial are funded by the COVID-19 Therapeutics Accelerator, an initiative with contributions from an array of public and philanthropic donors, including the Bill & Melinda Gates Foundation. Conducted at multiple sites in North America, Europe, the U.K. and Africa, CROWN CORONATION will evaluate the protective potential of weekly, twice weekly or daily doses of chloroquine, when compared with placebo, in frontline healthcare workers at high risk of exposure to SARS-CoV-2. The trial aims to include at least 30,000 subjects across the frontline healthcare workers.

The release said Natco Pharma has been supplying chloroquine phosphate tablets, which is an USFDA approved drug, through its marketing partner to the U.S since 2011. Recently, Natco’s alternate facility in Visakhapatnam has also been approved to supply the same drug.

A letter from the Editor


Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Support Quality Journalism
Related Topics
Recommended for you
This article is closed for comments.
Please Email the Editor

Printable version | May 26, 2020 3:39:22 AM | https://www.thehindu.com/news/cities/Hyderabad/natco-pharma-donates-chloroquine-phosphate-tablets-for-trial/article31626518.ece

Next Story